drug_type
RELEVANT_DRUG
intervention_type
Drug - Antibody–drug conjugate
drug_description
A HER3-directed antibody–drug conjugate consisting of a fully human anti-HER3 IgG1 linked via a cleavable linker to deruxtecan (DXd), a topoisomerase I inhibitor. It binds HER3, is internalized, and releases DXd to induce DNA damage and apoptosis; evaluated at 5.6 mg/kg IV every 3 weeks in advanced solid tumors with NRG1 fusions.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
patritumab deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Patritumab deruxtecan is a HER3-directed monoclonal antibody linked via a cleavable linker to the topoisomerase I inhibitor deruxtecan (DXd). Upon binding HER3 on tumor cells, the ADC is internalized and the linker is cleaved intracellularly to release DXd, causing topoisomerase I–mediated DNA damage that leads to cell-cycle arrest and apoptosis, with potential bystander killing; it may also inhibit NRG1–HER3 signaling.
drug_name
Patritumab deruxtecan (U3-1402)
nct_id_drug_ref
NCT06383884